Prostate specific antigen and pathological features of prostate cancer in black and white patients: A comparative study based on radical prostatectomy specimens

Journal of Urology

Volumn 160, Issue 2, 1998, Pages 437-442

  Pettaway, Curtis A ^a,b   Troncoso, Patricia ^a   Ramirez, Edilberto I ^a   Johnston, Dennis A ^a   Steelhammer, Linda ^a   Joseph Babaian, R ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Blacks; Pathology; Prostate specific antigen; Prostatic neoplasms; Whites

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL FEATURE; COMPARATIVE STUDY; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; ORGAN WEIGHT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; TUMOR VOLUME;

EID: 0032323805     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62919-7     Document Type: Article

References (33)

1. Wingo, P. A., Bolden, S., Tong, T., Parker, S. L., Martin, L. M. and Heath, C. W., Jr.: Cancer statistics for African Americans, 1996. CA, 46: 113, 1996.
2. Polednak, A. P. and Flannery, J. T.: Black versus white racial differences in clinical stage at diagnosis and treatment of prostatic cancer in Connecticut. Cancer, 70: 2152, 1992.
3. Targonski, P. V., Guinan, P. and Phillips, C. W.: Prostate cancer: the stage disadvantage in the black male. J. Natl. Med. Assn., 83: 1094, 1991.
4. Powell, I. J., Schwartz, K. and Hussain, M.: Removal of the financial barrier to health care: does it impact on prostate cancer at presentation and survival? A comparative study between black and white men in a Veterans Affairs system. Urology, 46: 825, 1995.
5. Brawn, P. N., Johnson, E. H., Kuhl, D. L., Riggs, M. W., Speights, V. O., Johnson, C. F., III, Pandya, P. P., Lind, M. L. and Bell, N. F.: Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer, 71: 2569, 1993.
6. Optenberg, S. A., Thompson, I. M., Friedrichs, P., Wojcik, B., Stein, C. R. and Kramer, B.: Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. J.A.M.A., 274: 1599, 1995.
7. Fowler, J. E., Jr. and Terrell, F.: Survival in blacks and whites after treatment for localized prostate cancer. J. Urol., 156: 133, 1996.
8. Moul, J. D., Douglas, T. H., McCarthy, W. F. and McLeod, D. G.: Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J. Urol., 155: 1667, 1996.
9. Powell, I. J., Heilbrun, L. K., Sakr, W., Grignon, D., Montie, J., Novaalo, M., Smith, D. and Pontes, J. E.: The predictive value of race as a clinical prognostic factor among patients with clinically localized prostate cancer: a multivariate analysis of positive surgical margins. Urology, 49: 726, 1997.
10. Morton, R. A., Jr.: Racial differences in adenocarcinoma of the prostate in North American men. Urology, 44: 637, 1994.
11. Mebane, C., Gibbs, T. and Horm, J.: Current status of prostate cancer in North American black males. J. Natl. Med. Assn., 82: 782, 1990.
12. Sakr, W. A., Grignon, D. J., Haas, G. P., Schomer, K. L., Heilbrun, L. K., Cassin, B. J., Powell, J., Montie, J. A. and Crissman, J. D.: Epidemiology of high grade prostate intraepithelial neoplasia. Path. Res. Practices, 191: 838, 1995.
13. Whittemore, A. S., Keller, J. B. and Betensky, R.: Low-grade, latent prostate cancer volume: predictor of clinical cancer incidence? J. Natl. Cancer Inst., 83: 1231, 1991.
14. Moul, J. D., Sesterhenn, I. A., Connelly, R. R., Douglas, T., Srivastava, S., Mostofi, F. K. and McLeod, D. G.: Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. J.A.M.A., 274: 1277, 1995.
15. Vijayakumar, S., Karrison, T., Weichselbaum, R. R., Chan, S., Quadri, S. F. and Awan, A. M.: Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol. Biomarkers Prev., 1: 541, 1992.
16. Babaian, R. J., Troncoso, P., Steelhammer, L. C., Lloreta-Trull, J. and Ramirez, E. I.: Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. J. Urol., 154: 1808, 1995.
17. Moul, J. D., Mooneyhan, R. M., Lin, T. H., Sesterhenn, I. A., Connelly, R. R., Douglas, T. H., Mostofi, F. K. and McLeod, D. G.: Three-dimensional (3D) computerized tumor volume determination in radical prostatectomy specimens from black and white patients. J. Urol., part 2, 155: 509A, abstract 794, 1996.
18. Schröder, F. H., Hermanek, P., Denis, L., Fair, W. R., Gospodarowicz, M. K. and Pavone-Macaluso, M.: The TNM classification of prostate cancer. Prostate, suppl., 4: 129, 1992.
19. Ayala, A. G., Ro, J. Y., Babaian, R. J., Troncoso, P. and Grignon, D. J.: The prostatic capsule: does it exist? Its importance in the staging and treatment of prostatic carcinoma. Amer. J. Surg. Path., 13: 21, 1989.
20. Gleason, D. F.: Histologic grading and clinical staging of prostatic carcinoma. In: Urologic Pathology: The Prostate. Edited by M. Tannenbaum. Philadelphia: Lea & Febiger, chapt. 9, pp. 171-197, 1977.
21. Sakr, W. A., Wheeler, T. M., Blute, M., Bodo, M., Calle-Rodrique, R., Henson, D. E., Mostofi, F. K., Seiffert, J., Wojno, W. and Zincke, H.: International consultation on prostatic intraepithelial neoplasia and pathologic staging of prostatic carcinoma: staging and reporting of prostate cancer-sampling of the radical prostatectomy specimen. Cancer, 78: 366, 1996.
22. Zar, J. M.: Biostatistical Analysis, 3rd ed.. Englewood Cliffs: Prentice Hall, pp. 407-418, 1996.
23. Troncoso, P., Babaian, R. J., Ro, J. Y., Grignon, D. J., von Eschenbach, A. C. and Ayala, A. G.: Prostatic intraepithelial neoplasia and invasive prostatic adenocarcinoma in cystoprostatectomy specimens. Urology, 34: 52, 1989.
24. McNeal, J. E., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Amer. J. Surg. Path., 12: 897, 1988.
25. Young, C. Y., Montgomery, B. T., Andrews, P. E., Qiu, S. D., Bilhartz, D. L. and Tindall, D. J.: Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res., 51: 3748, 1991.
26. Ross, R. K., Bernstein, L., Lobo, R. A., Shimizu, H., Stanczyk, F. Z., Pike, M. C. and Henderson, B. E.: 5-Alpha-reductase activity and risk of prostate cancer among Japanese and U.S. white and black males. Lancet, 339: 887, 1992.
27. Wu, A. H., Whittemore, A. S., Kolonel, L. N., John, E. M., Gallagher, R. P., West, D. W., Hankin, J., Teh, C. Z., Dreon, D. M. and Paffenberger, R. S., Jr.: Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol. Biomarkers Prev., 4: 735, 1995.
28. Vijayakumar, S., Quadri, S. F., Dong, L., Ignacio, L., Kathuria, I. N. S., Sutton, H. and Halpern, H.: Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer. J. Natl. Med. Assn., 87: 813, 1995.
29. Chamberlain, N. L., Driver, E. D. and Miesfeld, R. L.: The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucl. Acids Res., 22: 3181, 1994.
30. Irvine, R. A., Yu, M. C., Ross, R. K. and Coetzee, G. A.: The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res., 55: 1937, 1995.
31. Goivannucci, E., Stampfer, M., Krithivas, K., Brown, M., Talcott, J., Hennekens, C. and Kantoff, P.: The CAG repeat contained within the androgen receptor is a heritable factor that influences the clinical behavior of prostate cancer. Proc. Amer. Soc. Clin. Oncol., 15: A646, 1996.
32. Morgan, T. O., Jacobsen, S. J., McCarthy, W. F., Jacobsen, D. J., McLeod, D. G. and Moul, J. W.: Age-specific reference ranges for serum prostate-specific antigen in black men. New Engl. J. Med., 335: 304, 1996.
33. Henderson, R. J., Eastham, J. A., Culkin, D. J., Kattan, M. W., Whatley, T., Mata, J., Venable, D. and Sartor, O.: Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J. Natl. Cancer Inst., 89: 134, 1997.